Modality
Multispecific
MOA
IL-13i
Target
EGFR
Pathway
DDR
PsA
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
~Jul 2019
→ ~Oct 2020
Phase 3
~Jan 2021
→ ~Apr 2022
NDA/BLA
Jul 2022
→ Nov 2027
NDA/BLACurrent
NCT03823893
1,729 pts·PsA
2022-07→2027-11·Recruiting
1,729 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-111.6y awayPh3 Readout· PsA
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-11-11 · 1.6y away
PsA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03823893 | NDA/BLA | PsA | Recruiting | 1729 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |